By Nicholas G. Miller

Indivior said it plans to shift its domicile from the U.K. to the U.S., joining a wave of companies that have recently moved to the U.S. to gain more access to capital.

The drug-maker focused on the treatment of opioid dependence said it would establish a new U.S. parent company above its existing U.K. company in order to complete the move. Indivior previously listed its shares on the Nasdaq in June 2023 and cancelled its secondary listing on the London Stock Exchange in July.

The company said the change would give it a larger presence in U.S. capital markets and increase its participation in U.S. equity indexes. It would also allow for better collaboration with U.S. public health leaders on its treatment for opioid use disorder.

The move is expected to be completed in late January of next year, subject to a shareholder vote.

The U.S. stock market gives access to far more capital than European markets. Europeans invest less of their money in the stock market and institutional investors often invest in safer assets, such as government bonds.

As a result, a series of companies, including Flutter and Wise, have decided to move their listings from Europe to the U.S. in recent years. The number of listings in London has fallen by a fifth in just five years.

AstraZeneca said Monday it would start to directly list its shares on the NYSE but would retain its primary listing in London. On Tuesday, Diversified Energy said it would move its primary listing to the U.S. in order to elevate its stock valuation.

On Tuesday, Indivior said it reached a settlement with the state of New York over the marketing of its opioid overdose drug and would stop promoting the drug, called Opvee. The New York Attorney General's Office said the company marketed the drug to public officials throughout the state, despite knowing that Opvee is not authorized by the state's Department of Health for use without a prescription.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

October 01, 2025 09:26 ET (13:26 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.